What is Dolby Laboratories, Inc.'s earnings per share (EPS)?

Dolby Laboratories, Inc. (DLB) reported diluted earnings per share of $2.62 for fiscal year 2025. This represents a -2.6% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Dolby Laboratories, Inc. (DLB) Financials

DLB

Trailing 12 months to June 26, 2026

Revenue $1.4B +0.6% YoY

Net Income $226.2M -14.4% YoY

EPS (Diluted) $2.35 -13.6% YoY

Free Cash Flow $392.7M -10.4% YoY

Market Cap $5.5B as of Oct 3, 2026

Price / Sales 4.1x on $1.4B revenue, trailing 12 months to June 26, 2026

Price / Earnings 24.4x on $226.2M net income, trailing 12 months to June 26, 2026

Price / Book 2.1x on $2.6B equity, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 3, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Jun 26, 2026 Reported Jul 30, 2026 Currency USD FYE September

Newest figures come from the 10-Q for Q3 FY2026, filed Jul 30, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the DLB SEC filings page.

Dolby Laboratories, Inc. (DLB) reported $1.4B in revenue over the twelve months to Jun 26, 2026, up 0.6% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI DLB FY2025 2026-10-03

Dolby’s high-margin model converts revenue into cash efficiently, though operating profitability remains below its FY2021 peak.

FY2025’s free-cash-flow margin reached 32.3%, well above its 18.9% net margin. That spread, together with operating cash flow of $472M and modest capital spending, indicates that accounting earnings are converting into cash without heavy reinvestment.

Revenue reached $1.35B in FY2025 after remaining near $1.3B through FY2024. Gross margin stayed near 88%, so the latest top-line improvement did not require a visible sacrifice in unit economics; whether the increase came from volume, mix, or pricing is not distinguishable from these figures.

Operating margin recovered from 16.5% in FY2022 to 19.6% in FY2025, showing that the latest revenue lift reached operating profit rather than being swallowed by overhead. Balance-sheet posture is also conservative: debt-to-equity was 0.2x and the current ratio was 3.2x, providing substantial reported short-term coverage.

Financial Health Signals

Financial Health Score 74/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Dolby Laboratories, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Dolby Laboratories, Inc. has an operating margin of 19.6%, meaning the company retains $20 of operating profit per $100 of revenue. This strong profitability earns a score of 87/100, reflecting efficient cost management and pricing power. This is down from 20.3% the prior year.

Growth

Dolby Laboratories, Inc.'s revenue grew 5.9% year-over-year to $1.3B, a solid pace of expansion. This earns a growth score of 37/100.

Leverage

Dolby Laboratories, Inc. carries a low D/E ratio of 0.23, meaning only $0.23 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 74/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

With a current ratio of 3.17, Dolby Laboratories, Inc. holds $3.17 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 81/100.

Cash Flow

Dolby Laboratories, Inc. converts 32.3% of revenue into free cash flow ($435.9M). This strong cash generation earns a score of 93/100.

Returns

Dolby Laboratories, Inc. earns a strong 9.7% return on equity (ROE), meaning it generates $10 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 74/100. This is down from 10.6% the prior year.

Altman Z-Score Safe

7.74

Dolby Laboratories, Inc. scores 7.74, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($5.5B) relative to total liabilities ($595.8M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

5/7

Dolby Laboratories, Inc. passes 5 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 3 of 4 profitability signals pass, all 1 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Cash-Backed

1.85x

For every $1 of reported earnings, Dolby Laboratories, Inc. generates $1.85 in operating cash flow ($472.2M OCF vs $255.0M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage Safe

17.23x

Dolby Laboratories, Inc. earns $17.23 in operating income for every $1 of interest expense ($265.0M vs $15.4M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$305.0M

YoY-3.3%

QoQ-22.9%

5Y CAGR-0.9%

10Y CAGR+2.4%

Dolby Laboratories, Inc. generated $305.0M in revenue in Q3 2026. This represents a decrease of 3.3% from the same quarter a year earlier. Against the prior quarter it is down 22.9%.

EBITDA

$56.9M

YoY-18.2%

QoQ-58.5%

5Y CAGR-12.1%

Dolby Laboratories, Inc.'s EBITDA was $56.9M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 18.2% from the same quarter a year earlier. Against the prior quarter it is down 58.5%.

Net Income

$28.6M

YoY-37.9%

QoQ-69.9%

5Y CAGR-17.8%

10Y CAGR-0.8%

Dolby Laboratories, Inc. reported $28.6M in net income in Q3 2026. This represents a decrease of 37.9% from the same quarter a year earlier. Against the prior quarter it is down 69.9%.

EPS (Diluted)

$0.30

YoY-37.5%

QoQ-69.7%

5Y CAGR-16.3%

10Y CAGR0.0%

Dolby Laboratories, Inc. earned $0.30 per diluted share (EPS) in Q3 2026. This represents a decrease of 37.5% from the same quarter a year earlier. Against the prior quarter it is down 69.7%.

Cash & Balance Sheet

Free Cash Flow

$152.5M

YoY+148.9%

QoQ+82.7%

5Y CAGR+16.8%

10Y CAGR+13.5%

Dolby Laboratories, Inc. generated $152.5M in free cash flow in Q3 2026, representing cash available after capex. This represents an increase of 148.9% from the same quarter a year earlier. Against the prior quarter it is up 82.7%.

Cash & Debt

$669.4M

YoY-4.2%

QoQ+12.6%

5Y CAGR-9.5%

10Y CAGR+3.7%

Dolby Laboratories, Inc. held $669.4M in cash as of Q3 2026; long-term debt is not reported for that period.

Dividends Per Share

$0.36

YoY+9.1%

QoQ0.0%

5Y CAGR+10.4%

10Y CAGR+11.6%

Dolby Laboratories, Inc. paid $0.36 per share in dividends in Q3 2026. This represents an increase of 9.1% from the same quarter a year earlier. It is unchanged from the prior quarter.

Shares Outstanding

Diluted avg 95M

Dolby Laboratories, Inc. had a weighted average of 95M diluted shares in Q3 2026; the shares outstanding count is not reported for that period.

Margins & Returns

Gross Margin

86.8%

YoY+0.7pp

QoQ-1.9pp

5Y change-3.1pp

10Y change-0.9pp

Dolby Laboratories, Inc.'s gross margin was 86.8% in Q3 2026, indicating the percentage of revenue retained after direct costs. This is up 0.7 percentage points from the same quarter a year earlier. Against the prior quarter it is down 1.9 percentage points.

Operating Margin

11.3%

YoY-3.8pp

QoQ-17.3pp

5Y change-14.8pp

Dolby Laboratories, Inc.'s operating margin was 11.3% in Q3 2026, reflecting core business profitability. This is down 3.8 percentage points from the same quarter a year earlier. Against the prior quarter it is down 17.3 percentage points.

Net Margin

9.4%

YoY-5.2pp

QoQ-14.6pp

5Y change-14.5pp

10Y change-3.5pp

Dolby Laboratories, Inc.'s net profit margin was 9.4% in Q3 2026, showing the share of revenue converted to profit. This is down 5.2 percentage points from the same quarter a year earlier. Against the prior quarter it is down 14.6 percentage points.

Return on Equity

1.1%

YoY-0.7pp

QoQ-2.5pp

5Y change-1.8pp

10Y change-0.6pp

Dolby Laboratories, Inc.'s ROE was 1.1% in Q3 2026, measuring profit generated per dollar of shareholder equity. This is down 0.7 percentage points from the same quarter a year earlier. Against the prior quarter it is down 2.5 percentage points.

Capital Allocation

R&D Spending

$65.7M

YoY-0.4%

QoQ+3.3%

5Y CAGR0.0%

Dolby Laboratories, Inc. invested $65.7M in research and development in Q3 2026. This represents a decrease of 0.4% from the same quarter a year earlier. Against the prior quarter it is up 3.3%.

Share Buybacks

$65.0M

YoY-7.2%

QoQ0.0%

5Y CAGR-1.7%

10Y CAGR+5.1%

Dolby Laboratories, Inc. spent $65.0M on share buybacks in Q3 2026, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 7.2% from the same quarter a year earlier. It is unchanged from the prior quarter.

Capital Expenditures

$15.0M

YoY+133.2%

QoQ+65.4%

5Y CAGR+2.3%

10Y CAGR-4.7%

Dolby Laboratories, Inc. invested $15.0M in capex in Q3 2026, funding long-term assets and infrastructure. This represents an increase of 133.2% from the same quarter a year earlier. Against the prior quarter it is up 65.4%.

DLB Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

DLB quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	$1.4B	$1.3B+5.9%	$1.3B-2.0%	$1.3B+3.7%	$1.3B-2.1%	$1.3B+10.3%	$1.2B-6.4%	$1.2B+17.7%	$1.1B-2.4%	$1.1B+5.3%	$1.0B+5.7%	$970.6M+1.1%	$960.2M+5.6%	$909.7M-2.5%	$933.0M-2.9%	$961.1M
Cost of Revenue	$167.8M	$160.1M+14.0%	$140.5M-7.9%	$152.6M+7.9%	$141.4M+8.7%	$130.0M-11.2%	$146.5M-8.9%	$160.9M+26.1%	$127.6M+7.6%	$118.5M+8.8%	$109.0M+14.9%	$94.8M+35.1%	$70.2M-27.4%	$96.7M+5.1%	$92.0M-17.2%	$111.2M
Gross Profit	$1.2B	$1.2B+4.9%	$1.1B-1.2%	$1.1B+3.1%	$1.1B-3.4%	$1.2B+13.4%	$1.0B-6.1%	$1.1B+16.6%	$927.0M-3.6%	$961.6M+4.9%	$916.8M+4.7%	$875.8M-1.6%	$890.0M+9.5%	$813.0M-3.3%	$841.0M-1.0%	$849.9M
R&D Expenses	$265.9M	$261.8M-0.7%	$263.7M-2.9%	$271.5M+4.0%	$261.2M+3.0%	$253.6M+6.1%	$239.0M+0.5%	$237.9M+0.5%	$236.8M+1.5%	$233.3M+6.2%	$219.6M+9.1%	$201.3M+9.9%	$183.1M+8.5%	$168.7M+20.4%	$140.1M+13.1%	$123.9M
SG&A Expenses	$295.5M	$286.5M+6.0%	$270.4M+4.6%	$258.5M-6.1%	$275.3M+22.8%	$224.2M+2.0%	$219.8M+7.0%	$205.4M+4.1%	$197.4M+15.0%	$171.7M+1.7%	$168.9M-7.3%	$182.2M+2.3%	$178.1M+10.0%	$162.0M+8.6%	$149.2M+8.4%	$137.6M
Operating Income	$239.1M	$265.0M+2.6%	$258.3M+19.7%	$215.8M+4.4%	$206.6M-40.0%	$344.4M+57.4%	$218.7M-14.9%	$257.1M+40.1%	$183.5M-25.7%	$247.1M+6.6%	$231.8M+8.7%	$213.2M-22.1%	$273.7M+11.6%	$245.3M-32.2%	$362.0M-15.8%	$429.7M
EBITDA	N/A	$352.8M+5.7%	$333.9M+11.9%	$298.3M+1.1%	$295.1M-33.0%	$440.3M+42.2%	$309.6M-9.5%	$342.2M+29.2%	$264.8M-20.1%	$331.4M+4.6%	$316.9M+12.2%	$282.4M-13.7%	$327.0M+9.5%	$298.5M-26.5%	$405.9M-14.3%	$473.7M
Interest Expense	N/A	$15.4M-54.9%	$34.1M+21.3%	$28.1M+7028.4%	$394K-17.7%	$479K+157.5%	$186K+9.4%	$170K-14.1%	$198K+55.9%	$127K+1.6%	$125K-31.7%	$183K+200.0%	-$183K-131.8%	$575K+193.4%	$196K+119.1%	-$1.0M
Income Tax	$48.8M	$47.0M-2.4%	$48.2M-0.5%	$48.4M+54.3%	$31.4M-14.5%	$36.7M+353.2%	$8.1M-69.8%	$26.8M-82.6%	$154.1M+220.7%	$48.0M-3.0%	$49.5M-20.8%	$62.5M-7.2%	$67.4M+11.7%	$60.3M-41.9%	$103.9M-20.1%	$130.1M
Net Income	$226.2M	$255.0M-2.6%	$261.8M+30.5%	$200.7M+9.0%	$184.1M-40.7%	$310.2M+34.1%	$231.4M-9.3%	$255.2M+511.2%	$41.7M-79.8%	$206.5M+11.1%	$185.9M+2.5%	$181.4M-12.0%	$206.1M+8.9%	$189.3M-28.4%	$264.3M-14.5%	$309.3M
EPS (Basic)	N/A	$2.66-2.9%	$2.74+30.5%	$2.10+14.1%	$1.84-40.1%	$3.07+33.5%	$2.30-8.4%	$2.51+527.5%	$0.40-80.3%	$2.03+9.7%	$1.85+4.5%	$1.77-12.4%	$2.02+8.6%	$1.86-24.7%	$2.47-11.2%	$2.78
EPS (Diluted)	$2.35	$2.62-2.6%	$2.69+31.2%	$2.05+13.3%	$1.81-39.1%	$2.97+32.0%	$2.25-7.8%	$2.44+525.6%	$0.39-80.5%	$2.00+10.5%	$1.81+3.4%	$1.75-12.1%	$1.99+8.2%	$1.84-25.2%	$2.46-10.5%	$2.75
Diluted Shares (Avg)	N/A	97M+0.2%	97M-0.4%	98M-4.2%	102M-2.5%	105M+1.6%	103M-1.6%	105M-2.2%	107M+3.6%	103M+0.8%	102M-1.4%	104M+0.2%	104M+0.8%	103M-4.4%	108M-4.5%	113M

Metric	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K
Revenue	$305.0M-3.3%	$395.6M+7.1%	$346.7M-2.9%	$307.0M+0.7%	$315.5M+9.3%	$369.6M+1.4%	$357.0M+13.1%	$304.8M+4.9%
Cost of Revenue	$40.3M-8.4%	$44.7M+24.8%	$43.2M+6.0%	$39.5M+16.2%	$44.0M+23.4%	$35.8M-7.6%	$40.8M+27.2%	$34.0M-4.4%
Gross Profit	$264.7M-2.5%	$350.9M+5.1%	$303.5M-4.0%	$267.5M-1.2%	$271.5M+7.3%	$333.7M+2.4%	$316.2M+11.5%	$270.8M+6.2%
R&D Expenses	$65.7M-0.4%	$63.7M+3.2%	$69.1M+3.7%	$67.5M-1.7%	$66.0M+0.7%	$61.7M-1.3%	$66.6M-0.6%	$68.6M-2.5%
SG&A Expenses	$75.6M+4.5%	$76.0M+7.9%	$70.2M+0.2%	$73.7M+6.5%	$72.3M+4.4%	$70.4M+5.5%	$70.1M+7.6%	$69.2M+3.9%
Operating Income	$34.3M-28.0%	$112.9M+4.8%	$62.2M-22.2%	$29.7M-36.0%	$47.6M+29.5%	$107.8M-1.1%	$79.9M+20.6%	$46.4M+1426.7%
EBITDA	$56.9M-18.2%	$137.0M+6.0%	$86.3M-15.6%	$51.7M-23.7%	$69.6M+26.3%	$129.3M+1.8%	$102.2M+21.6%	$67.7M+284.0%
Income Tax	$14.6M+62.6%	$24.2M-13.5%	$17.9M-0.3%	-$8.0M-1020.0%	$9.0M-14.6%	$28.0M+19.1%	$18.0M+35.7%	$868K+199.2%
Net Income	$28.6M-37.9%	$94.9M+3.4%	$53.3M-21.4%	$49.3M-15.8%	$46.1M+19.8%	$91.8M-6.2%	$67.8M+1.3%	$58.6M+537.6%
EPS (Basic)	$0.30-37.5%	$1.00+5.3%	$0.56-21.1%	$0.52-14.8%	$0.48+20.0%	$0.95-6.9%	$0.71+1.4%	$0.61+510.0%
EPS (Diluted)	$0.30-37.5%	$0.99+5.3%	$0.55-21.4%	$0.51-15.0%	$0.48+20.0%	$0.94-6.9%	$0.70+1.4%	$0.60+566.7%
Diluted Shares (Avg)	95M-2.5%	96M-2.0%	97M-0.6%	N/A	97M-0.1%	97M+0.6%	97M-0.3%	N/A

Not reported in any period shown, so not listed: Interest Expense.

DLB Balance Sheet

DLB quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$3.2B+3.8%	$3.1B+4.4%	$3.0B+10.8%	$2.7B-13.4%	$3.1B+6.5%	$2.9B+3.4%	$2.8B-1.5%	$2.9B+13.1%	$2.5B+9.7%	$2.3B+8.3%	$2.1B+7.5%	$2.0B+14.2%	$1.7B-11.4%	$2.0B+4.1%	$1.9B
Current Assets	$1.4B+16.2%	$1.2B-19.7%	$1.5B+13.5%	$1.3B-25.5%	$1.8B+13.8%	$1.5B+12.0%	$1.4B-7.7%	$1.5B+48.0%	$1.0B+33.1%	$759.7M-7.5%	$821.2M-18.4%	$1.0B+22.9%	$818.6M-15.6%	$970.3M-16.3%	$1.2B
Cash & Equivalents	$701.9M+45.6%	$482.0M-35.3%	$745.4M+20.2%	$620.1M-49.4%	$1.2B+14.3%	$1.1B+34.5%	$797.2M-13.2%	$918.1M+44.7%	$634.4M+22.1%	$519.8M-2.3%	$531.9M-6.4%	$568.5M+25.1%	$454.4M-7.8%	$492.6M-10.7%	$551.5M
Short-Term Investments	$703K	$0-100.0%	$139.1M-26.5%	$189.2M+387.2%	$38.8M-17.3%	$46.9M-60.6%	$119.1M-33.1%	$178.1M-28.1%	$247.8M+103.7%	$121.6M-12.4%	$138.9M-39.9%	$231.2M+64.8%	$140.3M-53.7%	$302.7M-22.6%	$391.3M
Inventory	$30.4M-9.8%	$33.7M-5.3%	$35.6M+51.3%	$23.5M+114.8%	$11.0M-57.1%	$25.6M-21.0%	$32.3M+23.4%	$26.2M+4.6%	$25.1M+53.2%	$16.4M+17.9%	$13.9M+62.5%	$8.5M-15.4%	$10.1M-39.6%	$16.7M-36.4%	$26.2M
Accounts Receivable	$331.1M+5.0%	$315.5M+20.3%	$262.2M+7.7%	$243.6M+4.7%	$232.6M+29.0%	$180.3M-4.6%	$189.1M+13.8%	$166.1M+125.3%	$73.8M-2.6%	$75.7M-25.5%	$101.6M+17.9%	$86.2M-11.6%	$97.5M+124.1%	$43.5M-29.6%	$61.8M
Long-Term Investments	$80.2M-10.2%	$89.3M-8.7%	$97.8M-4.6%	$102.5M+63.2%	$62.8M+20.5%	$52.1M-71.0%	$179.6M-4.4%	$187.8M-40.3%	$314.4M-20.2%	$393.9M+22.7%	$321.0M+8.3%	$296.3M-3.3%	$306.3M-15.3%	$361.6M+32.6%	$272.8M
Goodwill	$529.9M-0.6%	$533.2M+30.6%	$408.4M+11.8%	$365.1M+7.2%	$340.7M+1.1%	$336.9M+0.6%	$334.8M+2.1%	$328.0M+5.4%	$311.1M+0.5%	$309.6M+0.6%	$307.7M+10.9%	$277.6M-0.8%	$279.7M-0.6%	$281.4M+6.9%	$263.3M
Total Liabilities	$595.8M-4.4%	$623.0M+2.5%	$607.6M+38.6%	$438.5M-12.5%	$501.5M+4.7%	$478.9M-5.9%	$508.7M+2.8%	$494.9M+27.0%	$389.7M+17.6%	$331.4M+4.4%	$317.3M+25.7%	$252.4M+6.1%	$237.9M+9.4%	$217.6M+9.3%	$199.0M
Current Liabilities	$437.8M+4.8%	$417.8M-1.0%	$422.2M+52.1%	$277.5M-12.1%	$315.7M+18.2%	$267.1M-13.0%	$306.9M+7.6%	$285.2M+16.0%	$245.8M+15.3%	$213.1M+1.6%	$209.7M+10.7%	$189.4M+9.6%	$172.8M+10.2%	$156.8M-1.6%	$159.4M
Non-Current Liabilities	$158.0M-23.0%	$205.2M+10.7%	$185.4M+15.1%	$161.0M-13.3%	$185.7M-12.3%	$211.8M+4.9%	$201.9M-3.7%	$209.7M+45.7%	$143.9M+21.7%	$118.3M+9.9%	$107.6M+70.8%	$63.0M-3.2%	$65.1M+7.2%	$60.7M+53.1%	$39.7M
Total Equity	$2.6B+5.9%	$2.5B+5.2%	$2.4B+4.8%	$2.2B-13.5%	$2.6B+6.8%	$2.4B+5.4%	$2.3B-2.4%	$2.4B+10.6%	$2.1B+8.4%	$2.0B+9.0%	$1.8B+5.7%	$1.7B+15.5%	$1.5B-13.9%	$1.7B+3.4%	$1.7B
Retained Earnings	$2.6B+5.6%	$2.5B+4.4%	$2.4B+4.1%	$2.3B-11.9%	$2.6B+6.7%	$2.4B+5.0%	$2.3B+0.6%	$2.3B+11.1%	$2.1B+7.5%	$1.9B+7.6%	$1.8B+8.5%	$1.7B+14.2%	$1.5B-14.9%	$1.7B+18.3%	$1.4B

Metric	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K
Total Assets	$3.2B-1.2%	$3.2B+0.6%	$3.2B+1.1%	$3.2B+3.8%	$3.2B+7.5%	$3.2B+6.1%	$3.2B+7.6%	$3.1B+4.4%
Current Assets	$1.3B-0.9%	$1.4B+1.8%	$1.4B+9.5%	$1.4B+16.2%	$1.3B-8.9%	$1.4B-10.5%	$1.3B-11.4%	$1.2B-19.7%
Cash & Equivalents	$669.4M-4.2%	$594.3M-5.2%	$643.8M+23.6%	$701.9M+45.6%	$698.6M-5.8%	$626.6M-11.7%	$520.8M-20.7%	$482.0M-35.3%
Short-Term Investments	$652K-14.5%	$460K	$739K	$703K	$763K-99.4%	$0-100.0%	$0-100.0%	$0-100.0%
Inventory	$30.8M-5.1%	$31.9M-7.7%	$31.3M-1.8%	$30.4M-9.8%	$32.4M-6.6%	$34.6M-3.4%	$31.8M-15.3%	$33.7M-5.3%
Accounts Receivable	$285.1M-4.2%	$391.3M+24.6%	$373.1M+10.0%	$331.1M+5.0%	$297.6M+4.1%	$314.1M+11.3%	$339.3M+15.7%	$315.5M+20.3%
Long-Term Investments	$86.4M+10.8%	$81.2M+10.1%	$85.0M-1.5%	$80.2M-10.2%	$78.0M-33.8%	$73.8M-42.4%	$86.3M-7.1%	$89.3M-8.7%
Goodwill	$528.3M-0.1%	$529.7M+0.9%	$530.3M+1.9%	$529.9M-0.6%	$528.8M+29.5%	$525.0M+28.5%	$520.4M+26.8%	$533.2M+30.6%
Total Liabilities	$563.9M-3.1%	$622.4M-3.7%	$589.3M-8.2%	$595.8M-4.4%	$581.8M+10.6%	$646.0M+6.4%	$641.6M+11.9%	$623.0M+2.5%
Current Liabilities	$416.3M+7.1%	$474.6M+3.7%	$443.5M+0.4%	$437.8M+4.8%	$388.8M+9.7%	$457.5M+3.3%	$441.9M+12.1%	$417.8M-1.0%
Non-Current Liabilities	$147.6M-23.5%	$147.8M-21.6%	$145.7M-27.0%	$158.0M-23.0%	$193.0M+12.4%	$188.5M+14.9%	$199.7M+11.5%	$205.2M+10.7%
Total Equity	$2.6B-0.8%	$2.6B+1.7%	$2.6B+3.4%	$2.6B+5.9%	$2.6B+7.1%	$2.6B+6.3%	$2.5B+6.9%	$2.5B+5.2%
Retained Earnings	$2.6B-0.7%	$2.6B+1.1%	$2.6B+2.4%	$2.6B+5.6%	$2.6B+6.3%	$2.6B+6.2%	$2.5B+7.4%	$2.5B+4.4%

Not reported in any period shown, so not listed: Long-Term Debt.

DLB Cash Flow Statement

DLB quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	$437.6M	$472.2M+44.3%	$327.3M-10.9%	$367.1M+15.2%	$318.6M-28.9%	$447.8M+30.2%	$343.8M+4.9%	$327.7M-7.0%	$352.2M-6.8%	$377.8M+4.9%	$360.1M+16.4%	$309.4M-14.4%	$361.5M+30.8%	$276.5M-29.1%	$389.9M-3.4%	$403.7M
Depreciation & Amortization	N/A	$87.8M+16.2%	$75.6M-8.5%	$82.6M-6.7%	$88.5M-7.7%	$95.9M+5.5%	$90.9M+6.8%	$85.1M+4.7%	$81.3M-3.6%	$84.3M-1.0%	$85.2M+23.2%	$69.1M+29.8%	$53.3M+0.1%	$53.2M+21.4%	$43.9M-0.3%	$44.0M
Stock-Based Compensation	N/A	$128.5M+7.3%	$119.8M+1.1%	$118.5M+3.1%	$114.9M+15.3%	$99.7M+15.1%	$86.6M+13.1%	$76.6M+7.5%	$71.2M+9.0%	$65.3M-2.5%	$67.0M-0.1%	$67.1M+2.1%	$65.7M+2.1%	$64.3M+35.2%	$47.6M+9.0%	$43.7M
Capital Expenditures	$44.9M	$36.3M+21.1%	$30.0M-1.1%	$30.3M-36.7%	$47.9M-12.0%	$54.5M-17.9%	$66.3M-31.1%	$96.3M+32.2%	$72.8M-26.9%	$99.6M-1.1%	$100.8M-36.0%	$157.5M+109.0%	$75.4M+182.1%	$26.7M-84.0%	$167.3M+253.3%	$47.4M
Free Cash Flow	$392.7M	$435.9M+46.6%	$297.2M-11.7%	$336.7M+24.4%	$270.6M-31.2%	$393.3M+41.7%	$277.5M+19.9%	$231.4M-17.2%	$279.4M+0.4%	$278.2M+7.3%	$259.3M+70.8%	$151.9M-46.9%	$286.2M+14.6%	$249.8M+12.2%	$222.6M-37.5%	$356.3M
Investing Cash Flow	-$76.5M	-$10.6M+96.3%	-$286.3M-628.2%	$54.2M+118.3%	-$295.9M-559.0%	-$44.9M-133.4%	$134.4M+339.0%	-$56.2M-172.0%	$78.1M+149.4%	-$158.0M+44.1%	-$282.5M-38.8%	-$203.6M+0.7%	-$204.9M-217.1%	$175.0M+189.8%	-$194.8M+17.7%	-$236.7M
Financing Cash Flow	-$376.8M	-$247.2M+14.1%	-$287.8M-21.5%	-$236.8M+61.2%	-$610.6M-141.8%	-$252.5M-21.5%	-$207.8M+46.1%	-$385.3M-188.3%	-$133.6M-25.1%	-$106.8M-16.1%	-$92.0M+33.6%	-$138.5M-241.3%	-$40.6M+91.7%	-$488.0M-91.9%	-$254.3M-56.5%	-$162.5M
Dividends Paid	$134.3M	$126.6M+10.5%	$114.6M+10.8%	$103.4M+3.3%	$100.1M+12.2%	$89.2M+0.7%	$88.6M+14.3%	$77.5M+17.1%	$66.2M+15.9%	$57.1M+17.9%	$48.4M+18.0%	$41.0M	$0-100.0%	$408.2M	$0	$0
Share Buybacks	$235.0M	$125.0M-21.9%	$160.0M+7.2%	$149.3M-71.9%	$530.5M+115.8%	$245.9M+41.5%	$173.7M-49.0%	$340.6M+126.3%	$150.5M+50.5%	$100.0M-0.8%	$100.9M-6.1%	$107.3M+91.6%	$56.0M-31.9%	$82.2M-69.3%	$268.2M+39.4%	$192.4M

Metric	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K
Operating Cash Flow	$167.5M+147.4%	$92.5M-47.1%	$54.8M-48.7%	$122.8M+5.7%	$67.7M+218.3%	$174.9M-3.6%	$106.8M+1169.8%	$116.2M+36.6%
Depreciation & Amortization	$22.6M+3.1%	$24.1M+11.9%	$24.1M+8.0%	$22.0M+3.0%	$21.9M+19.8%	$21.5M+19.5%	$22.4M+25.1%	$21.4M+1.1%
Stock-Based Compensation	$31.0M+0.8%	$30.7M+0.1%	$37.2M+3.2%	N/A	$30.7M+4.7%	$30.7M+6.0%	$36.1M+13.1%	N/A
Capital Expenditures	$15.0M+133.2%	$9.1M+31.4%	$4.6M-31.7%	$16.2M+120.1%	$6.4M-15.6%	$6.9M-22.6%	$6.8M+11.1%	$7.4M-9.8%
Free Cash Flow	$152.5M+148.9%	$83.4M-50.3%	$50.2M-49.8%	$106.6M-2.0%	$61.3M+348.8%	$168.0M-2.6%	$100.0M+4229.0%	$108.8M+41.6%
Investing Cash Flow	-$9.8M-52.3%	-$46.1M-278.0%	$1.2M+115.3%	-$21.9M+91.6%	-$6.4M+17.0%	$25.9M+244.9%	-$8.1M-1386.1%	-$261.3M-1225.7%
Financing Cash Flow	-$91.0M-49.8%	-$99.9M-54.0%	-$121.8M-111.6%	-$64.1M-6.5%	-$60.7M-4.0%	-$64.9M-46.9%	-$57.6M+54.0%	-$60.1M-40.5%
Dividends Paid	$34.0M+7.5%	$34.3M+8.0%	$34.3M+8.8%	$31.6M+0.3%	$31.6M+10.5%	$31.8M+10.8%	$31.5M+10.5%	$31.5M+22.0%
Share Buybacks	$65.0M-7.2%	$65.0M+85.7%	$70.0M+366.7%	$35.0M+75.0%	$70.0M+100.0%	$35.0M+40.0%	$15.0M-81.3%	$20.0M-20.0%

DLB Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

DLB quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	88.1%-0.8pp	89.0%+0.7pp	88.3%-0.5pp	88.7%-1.1pp	89.8%+2.5pp	87.4%+0.4pp	87.0%-0.9pp	87.9%-1.1pp	89.0%-0.4pp	89.4%-0.8pp	90.2%-2.5pp	92.7%+3.3pp	89.4%-0.8pp	90.1%+1.7pp	88.4%
Operating Margin	19.6%-0.6pp	20.3%+3.7pp	16.6%+0.1pp	16.5%-10.4pp	26.9%+8.0pp	18.8%-1.9pp	20.7%+3.3pp	17.4%-5.5pp	22.9%+0.3pp	22.6%+0.6pp	22.0%-6.5pp	28.5%+1.6pp	27.0%-11.8pp	38.8%-5.9pp	44.7%
Net Margin	18.9%-1.7pp	20.6%+5.1pp	15.4%+0.8pp	14.7%-9.5pp	24.2%+4.3pp	19.9%-0.6pp	20.5%+16.6pp	4.0%-15.2pp	19.1%+1.0pp	18.1%-0.6pp	18.7%-2.8pp	21.5%+0.7pp	20.8%-7.5pp	28.3%-3.8pp	32.2%
Return on Equity	9.7%-0.9pp	10.6%+2.1pp	8.5%+0.3pp	8.2%-3.7pp	11.9%+2.4pp	9.5%-1.6pp	11.1%+9.3pp	1.8%-7.9pp	9.7%+0.2pp	9.4%-0.6pp	10.0%-2.0pp	12.0%-0.7pp	12.8%-2.6pp	15.4%-3.2pp	18.6%
Return on Assets	7.9%-0.5pp	8.4%+1.7pp	6.7%-0.1pp	6.8%-3.1pp	10.0%+2.1pp	7.9%-1.1pp	9.0%+7.6pp	1.5%-6.7pp	8.2%+0.1pp	8.1%-0.5pp	8.5%-1.9pp	10.4%-0.5pp	10.9%-2.6pp	13.5%-2.9pp	16.4%
Current Ratio	3.17+0.3x	2.86-0.7x	3.52-1.2x	4.72-0.9x	5.58-0.2x	5.79+1.3x	4.50-0.7x	5.25+1.1x	4.12+0.5x	3.57-0.4x	3.92-1.4x	5.31+0.6x	4.74-1.4x	6.19-1.1x	7.27
Debt-to-Equity	0.230.0x	0.250.0x	0.26+0.1x	0.200.0x	0.190.0x	0.200.0x	0.220.0x	0.210.0x	0.180.0x	0.170.0x	0.180.0x	0.150.0x	0.160.0x	0.130.0x	0.12
Asset Turnover	0.420.0x	0.410.0x	0.440.0x	0.47+0.1x	0.410.0x	0.400.0x	0.44+0.1x	0.37-0.1x	0.430.0x	0.440.0x	0.460.0x	0.480.0x	0.520.0x	0.480.0x	0.51
FCF Margin	32.3%+9.0pp	23.3%-2.6pp	25.9%+4.3pp	21.6%-9.1pp	30.7%+6.8pp	23.9%+5.2pp	18.6%-7.9pp	26.5%+0.7pp	25.8%+0.5pp	25.3%+9.6pp	15.6%-14.2pp	29.8%+2.3pp	27.5%+3.6pp	23.9%-13.2pp	37.1%

Metric	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K
Gross Margin	86.8%+0.7pp	88.7%-1.6pp	87.5%-1.0pp	87.1%-1.7pp	86.1%-1.6pp	90.3%+0.9pp	88.6%-1.3pp	88.8%+1.1pp
Operating Margin	11.3%-3.8pp	28.5%-0.6pp	17.9%-4.5pp	9.7%-5.5pp	15.1%+2.4pp	29.2%-0.7pp	22.4%+1.4pp	15.2%+16.4pp
Net Margin	9.4%-5.2pp	24.0%-0.9pp	15.4%-3.6pp	16.1%-3.1pp	14.6%+1.3pp	24.8%-2.0pp	19.0%-2.2pp	19.2%+16.1pp
Return on Equity	1.1%-0.7pp	3.6%+0.1pp	2.1%-0.6pp	1.9%-0.5pp	1.8%+0.2pp	3.6%-0.5pp	2.7%-0.2pp	2.4%+2.0pp
Return on Assets	0.9%-0.5pp	2.9%+0.1pp	1.7%-0.5pp	1.5%-0.4pp	1.4%+0.1pp	2.8%-0.4pp	2.1%-0.1pp	1.9%+1.6pp
Current Ratio	3.19-0.3x	2.98-0.1x	3.17+0.3x	3.17+0.3x	3.44-0.7x	3.04-0.5x	2.91-0.8x	2.86-0.7x
Debt-to-Equity	0.220.0x	0.240.0x	0.230.0x	0.230.0x	0.220.0x	0.250.0x	0.260.0x	0.250.0x
Asset Turnover	0.100.0x	0.120.0x	0.110.0x	0.100.0x	0.100.0x	0.110.0x	0.110.0x	0.100.0x
FCF Margin	50.0%+30.6pp	21.1%-24.4pp	14.5%-13.5pp	34.7%-1.0pp	19.4%+14.7pp	45.5%-1.9pp	28.0%+27.3pp	35.7%+9.2pp

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Dolby Laboratories, Inc. DLB	FY2025	$1.3B	$255.0M	18.9%	$5.5B	74/100
Amentum Holdings, Inc. AMTM	FY2025	$14.4B	$66.0M	0.5%	$4.5B	45/100
MAXIMUS, Inc. MMS	FY2025	$5.4B	$319.0M	5.9%	$2.8B	55/100
AZZ Inc. AZZ	FY2026	$1.7B	$317.3M	19.2%	$4.1B	63/100
Unifirst Corp UNF	FY2025	$2.4B	$148.3M	6.1%	$4.6B	63/100
ABM Industries, Inc. ABM	FY2025	$8.7B	$162.4M	1.9%	$2.8B	42/100

Where Dolby Laboratories, Inc. Ranks

Frequently Asked Questions

What is Dolby Laboratories, Inc.'s annual revenue?

Dolby Laboratories, Inc. (DLB) reported $1.3B in total revenue for fiscal year 2025. This represents a 5.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Dolby Laboratories, Inc.'s revenue growing?

Dolby Laboratories, Inc. (DLB) revenue grew by 5.9% year-over-year, from $1.3B to $1.3B in fiscal year 2025.

Is Dolby Laboratories, Inc. profitable?

Yes, Dolby Laboratories, Inc. (DLB) reported a net income of $255.0M in fiscal year 2025, with a net profit margin of 18.9%.

What is Dolby Laboratories, Inc.'s EBITDA?

Dolby Laboratories, Inc. (DLB) had EBITDA of $352.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Dolby Laboratories, Inc.'s gross margin?

Dolby Laboratories, Inc. (DLB) had a gross margin of 88.1% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Dolby Laboratories, Inc.'s operating margin?

Dolby Laboratories, Inc. (DLB) had an operating margin of 19.6% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Dolby Laboratories, Inc.'s net profit margin?

Dolby Laboratories, Inc. (DLB) had a net profit margin of 18.9% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Does Dolby Laboratories, Inc. pay dividends?

Yes, Dolby Laboratories, Inc. (DLB) paid $1.32 per share in dividends during fiscal year 2025.

What is Dolby Laboratories, Inc.'s return on equity (ROE)?

Dolby Laboratories, Inc. (DLB) has a return on equity of 9.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Dolby Laboratories, Inc.'s free cash flow?

Dolby Laboratories, Inc. (DLB) generated $435.9M in free cash flow during fiscal year 2025. This represents a 46.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Dolby Laboratories, Inc.'s operating cash flow?

Dolby Laboratories, Inc. (DLB) generated $472.2M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Dolby Laboratories, Inc.'s total assets?

Dolby Laboratories, Inc. (DLB) had $3.2B in total assets as of fiscal year 2025, including both current and long-term assets.

What are Dolby Laboratories, Inc.'s capital expenditures?

Dolby Laboratories, Inc. (DLB) invested $36.3M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Dolby Laboratories, Inc. spend on research and development?

Dolby Laboratories, Inc. (DLB) invested $261.8M in research and development during fiscal year 2025.

Does Dolby Laboratories, Inc. buy back shares?

Yes, Dolby Laboratories, Inc. (DLB) spent $125.0M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

What is Dolby Laboratories, Inc.'s current ratio?

Dolby Laboratories, Inc. (DLB) had a current ratio of 3.17 as of fiscal year 2025, which is generally considered healthy.

What is Dolby Laboratories, Inc.'s debt-to-equity ratio?

Dolby Laboratories, Inc. (DLB) had a debt-to-equity ratio of 0.23 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Dolby Laboratories, Inc.'s return on assets (ROA)?

Dolby Laboratories, Inc. (DLB) had a return on assets of 7.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Dolby Laboratories, Inc.'s P/E ratio?

Dolby Laboratories, Inc. (DLB) trades at 24.4x earnings, its market capitalization divided by net income of $226.2M net income, trailing 12 months to June 26, 2026. The market capitalization is $5.5B as of Oct 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Dolby Laboratories, Inc.'s price-to-sales ratio?

Dolby Laboratories, Inc. (DLB) trades at 4.1x sales, its market capitalization divided by revenue of $1.4B revenue, trailing 12 months to June 26, 2026. The market capitalization is $5.5B as of Oct 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Dolby Laboratories, Inc.'s Altman Z-Score?

Dolby Laboratories, Inc. (DLB) has an Altman Z-Score of 7.74, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Dolby Laboratories, Inc.'s Piotroski F-Score?

Dolby Laboratories, Inc. (DLB) has a Piotroski F-Score of 5 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Dolby Laboratories, Inc.'s earnings high quality?

Dolby Laboratories, Inc. (DLB) has an earnings quality ratio of 1.85x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Dolby Laboratories, Inc. cover its interest payments?

Dolby Laboratories, Inc. (DLB) has an interest coverage ratio of 17.23x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Dolby Laboratories, Inc.?

Dolby Laboratories, Inc. (DLB) scores 74 out of 100 on our Financial Health Score, indicating strong standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.